Pacer Advisors
KNSA icon

Pacer Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Pacer Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-345
Closed -$6.44K – 2628
2024
Q2 		$6.44K Sell
345
-315
-48% -$5.9K ﹤0.01% 3612
2024
Q1 		$13K Buy
+660
New +$12.9K ﹤0.01% 3501
2021
Q2 		– Sell
-1,503
Closed -$28K – 1481
2021
Q1 		$28K Sell
1,503
-870
-37% -$17.8K ﹤0.01% 1487
2020
Q4 		$42K Buy
+2,373
New +$41.7K ﹤0.01% 1432

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Pacer Advisors's KNSA Position: Q3 2024 in Review

Pacer Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2024, closing a stake of 345 shares — an estimated $6.44K sold.

Pacer Advisors first reported a position in KNSA in Q4 2020 and held it in 4 quarters. The position peaked at $42K in Q4 2020. 176 funds tracked by Wall St. Rank hold KNSA as of Q3 2024.

  • Pacer Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 345 Kiniksa Pharmaceuticals shares in Q3 2024, an estimated $6.44K.
  • Pacer Advisors first reported a position in Kiniksa Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Kiniksa Pharmaceuticals position peaked at $42K in Q4 2020.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.